Scinai Immunotherapeutics (ADR) (SCNI)
Runs an Israeli CDMO alongside antibody programs for inflammation and immunology.
Something off on this page? Send us feedback.
Provides development and manufacturing services for clinical-stage biologics, sterile products and small-molecule APIs while developing inflammation and immunology antibodies. Revenue comes from CDMO services; therapeutic candidates are intended for licensing or strategic alliances and depend on licensed research rights, development and regulatory approvals.
Provides contract development and manufacturing services for emerging biotechnology customers alongside an inflammation and immunology research pipeline. Scinai Biopharma Services performs analytical-method and process development, biologic drug-substance work, small-molecule API development and manufacture, formulation, aseptic fill and finish, testing, and quality services. Jerusalem focuses on biologics and sterile products, while Yavne adds small-molecule API development, synthesis, analytics and GMP manufacture.
Develops PC111 for pemphigus and severe blistering skin diseases, plus VHH/NanoAb antibody formats for inflammatory conditions. No therapeutic product is approved or commercially marketed; candidates are intended for licensing or strategic alliances. CDMO revenue depends on contracts and customer retention, while licensed research rights, external funding, clinical development and regulatory approvals shape the therapeutic business. All employees and manufacturing operations are in Israel.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.9M · Total debt $3.6M · Total assets $17.2M · Shareholders' equity $11.7M
- Revenue
- $467.9K
- Operating income
- −$2.2M
- Net income
- −$2.0M
No dividends on record.
129 ADS as of Aug 25, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Uri Ben-Or1Insiderdirector | — | — | Form 4filed Mar 18, 2026 ↗ |
Mark Germain1Insiderdirector | — | — | Form 4filed Jun 18, 2026 ↗ |
Jay GreenInsiderdirector | 0.00% | 0 | Form 4filed Mar 18, 2026 ↗ |
LCK JNK 1 LLCStrategic | —9.50% of class, as filed | — | 13Gfiled Mar 4, 2025 ↗ |
Yael MargolinInsiderdirector | 0.00% | 0 | Form 4filed Mar 18, 2026 ↗ |
| See all 11 → | |||
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Thermo Fisher Scientific
Patheon overlaps across early-stage biologics and API CDMO work.
- Novartis (ADR)
Cosentyx is an established IL-17 psoriasis and PsA therapy.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Scinai Immunotherapeutics (ADR) | $2.05 | −12.75% | $1.2M | — | — | 0.8 | +305.2% |
| Thermo Fisher Scientific | $609.99 | +0.25% | $226.15B | 32.7 | 23.2 | 4.9 | +10.5% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 28.6 | 20.3 | 5.2 | +5.7% |